Bionomics’ (BNOX) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Bionomics (NASDAQ:BNOX) in a research report report published on Thursday morning, Benzinga reports. They currently have a $8.00 price target on the stock.

Bionomics Price Performance

Bionomics stock opened at $0.84 on Thursday. Bionomics has a fifty-two week low of $0.65 and a fifty-two week high of $6.41. The company’s 50 day simple moving average is $0.81 and its 200 day simple moving average is $0.97.

Bionomics Company Profile

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.